AU2018322305B2 - Cytocidal agent - Google Patents

Cytocidal agent Download PDF

Info

Publication number
AU2018322305B2
AU2018322305B2 AU2018322305A AU2018322305A AU2018322305B2 AU 2018322305 B2 AU2018322305 B2 AU 2018322305B2 AU 2018322305 A AU2018322305 A AU 2018322305A AU 2018322305 A AU2018322305 A AU 2018322305A AU 2018322305 B2 AU2018322305 B2 AU 2018322305B2
Authority
AU
Australia
Prior art keywords
peptide
cngb3
leu ala
amino acids
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018322305A
Other languages
English (en)
Other versions
AU2018322305A1 (en
Inventor
Michiko Fukuda
Naohiro Kanayama
Motohiro Nonaka
Yuichiro ONODERA
Toshiaki Shibata
Kazuhiro Sugihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujita Health University
Original Assignee
Fujita Health University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujita Health University filed Critical Fujita Health University
Publication of AU2018322305A1 publication Critical patent/AU2018322305A1/en
Application granted granted Critical
Publication of AU2018322305B2 publication Critical patent/AU2018322305B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018322305A 2017-08-24 2018-08-23 Cytocidal agent Active AU2018322305B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-161556 2017-08-24
JP2017161556A JP6613499B2 (ja) 2017-08-24 2017-08-24 細胞殺傷剤
PCT/JP2018/031136 WO2019039540A1 (ja) 2017-08-24 2018-08-23 細胞殺傷剤

Publications (2)

Publication Number Publication Date
AU2018322305A1 AU2018322305A1 (en) 2020-03-05
AU2018322305B2 true AU2018322305B2 (en) 2021-05-20

Family

ID=65438932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018322305A Active AU2018322305B2 (en) 2017-08-24 2018-08-23 Cytocidal agent

Country Status (9)

Country Link
US (2) US11357819B2 (enExample)
EP (1) EP3738601A4 (enExample)
JP (1) JP6613499B2 (enExample)
KR (1) KR102427844B1 (enExample)
CN (1) CN111065403B (enExample)
AU (1) AU2018322305B2 (enExample)
CA (1) CA3073392C (enExample)
SG (1) SG11202001484QA (enExample)
WO (1) WO2019039540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
WO2019138944A1 (ja) 2018-01-09 2019-07-18 学校法人藤田学園 細胞殺傷剤
JP2024517518A (ja) * 2021-05-07 2024-04-23 ツインピグ バイオラブ インコーポレイテッド マクロファージを標的とするペプチド、ならびにそのコンジュゲート、組成物、および使用
CN115725968A (zh) * 2022-11-18 2023-03-03 东莞宜安科技股份有限公司 一种生物医用钛合金表面的复合涂层及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2634934A1 (en) * 2005-12-23 2007-07-05 The Burnham Institute For Medical Research Endometriosis cell targeting peptide and uses thereof
EP2414389A1 (en) * 2009-04-01 2012-02-08 Schmidt-Wolf, Ingo Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides
WO2011027312A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS
JP6184101B2 (ja) * 2009-12-23 2017-08-23 サンフォード−バーナム メディカル リサーチ インスティテュート アネキシン１結合化合物に関する方法および組成物
EP3238782A3 (en) * 2010-04-06 2018-01-03 ExoCyte Therapeutics Pte, LTD Methods of treating cancer
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US10338068B2 (en) * 2013-07-08 2019-07-02 The Trustees Of Columbia University In The City Of New York Selection of biological objects
JPWO2015041019A1 (ja) * 2013-09-18 2017-03-02 国立大学法人京都大学 子宮内膜症様細胞の作製方法および子宮内膜症モデル動物
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
RU2571551C1 (ru) 2015-04-16 2015-12-20 Закрытое акционерное общество "ПЕПТЕК" Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017161556A (ja) 2017-06-27 2017-09-14 パイオニア株式会社 位置認識装置、制御方法、プログラム、及び記憶媒体
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Also Published As

Publication number Publication date
CN111065403B (zh) 2023-09-26
CA3073392A1 (en) 2019-02-28
WO2019039540A1 (ja) 2019-02-28
JP2019038772A (ja) 2019-03-14
KR20200031670A (ko) 2020-03-24
JP6613499B2 (ja) 2019-12-04
CN111065403A (zh) 2020-04-24
SG11202001484QA (en) 2020-03-30
KR102427844B1 (ko) 2022-07-29
US20200289608A1 (en) 2020-09-17
EP3738601A4 (en) 2021-06-16
CA3073392C (en) 2023-02-21
EP3738601A1 (en) 2020-11-18
AU2018322305A1 (en) 2020-03-05
US20220280596A1 (en) 2022-09-08
US11357819B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
US20220280596A1 (en) Cytocidal agent
Zhang et al. Sac-1004, a vascular leakage blocker, reduces cerebral ischemia—reperfusion injury by suppressing blood–brain barrier disruption and inflammation
Lee et al. PACAP inhibits tumor growth and interferes with clusterin in cervical carcinomas
Yang et al. Upregulation of Parkinson's disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer
Yuan et al. The human milk-derived peptide drives rapid regulation of macrophage inflammation responses in the neonatal intestine
Guo et al. Myocardial fibrosis induced by nonylphenol and its regulatory effect on the TGF-β1/LIMK1 signaling pathway
US20240417439A1 (en) RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT
Kim et al. Clusterin interaction with Bcl-xL is associated with seizure-induced neuronal death
JP2021518357A (ja) 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法
Ghatak et al. Heat shock protein 70 in penile neurovascular regeneration requires cystathionine gamma-lyase
US9581598B2 (en) Diagnosis and treatment of brain tumor
CA3087744C (en) CYTOCIDAL AGENT
HK40023962A (zh) 细胞杀伤剂
Wang et al. Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery
Yuan et al. Targeted intracellular delivery of BH3 mimetic peptide inhibits BCL-2 activity and prevents breast cancer development
HK40032209A (en) Cytocide
WO2019154515A1 (en) Methods and compositions for the treatment of amyloid diseases
Zhang Communication between midgut enterocytes and other cell types in adult Drosophila
Zhou Selective knockdown of misfolded SOD1 as a therapy for amyotrophic lateral sclerosis
CN109311962A (zh) Bcl-2 l10/ip3受体相互作用的抑制剂
Jin et al. Epithelial ovarian cancer: feasibility of image-guided intratumoral radiofrequency hyperthermia-enhanced direct gene therapy
Chiou Redefining the Role of H-Ferritin in the Brain
Jin Development of a small alpha-synuclein-knockdown peptide as a potential therapy for Parkinson’s disease
JP2021534826A (ja) がんの処置のためのペプチド治療薬およびその使用
JP2020030120A (ja) 疾患発症可能性の評価方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)